These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18036286)

  • 1. A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders.
    Figiel G; Sadowsky C
    Curr Med Res Opin; 2008 Jan; 24(1):157-66. PubMed ID: 18036286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease.
    Finkel SI
    Clin Ther; 2004 Jul; 26(7):980-90. PubMed ID: 15336465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
    Robert P
    Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease.
    Grossberg GT
    Curr Med Res Opin; 2005 Oct; 21(10):1631-9. PubMed ID: 16238903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
    Rösler M
    Int J Clin Pract Suppl; 2002 Jun; (127):20-36. PubMed ID: 12139365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J; Morgan S; Walker Z
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
    Bullock R; Cameron A
    Curr Med Res Opin; 2002; 18(5):258-64. PubMed ID: 12240787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivastigmine in Parkinson's disease dementia.
    Chitnis S; Rao J
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):941-55. PubMed ID: 19619073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
    Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
    Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.
    Dujardin K; Devos D; Duhem S; Destée A; Marié RM; Durif F; Lacomblez L; Touchon J; Pollak P; Péré JJ
    J Neurol; 2006 Sep; 253(9):1154-9. PubMed ID: 16998649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of rivastigmine on neuropsychiatric symptoms in the early stages of Parkinson's disease: A systematic review.
    Reilly S; Dhaliwal S; Arshad U; Macerollo A; Husain N; Costa AD
    Eur J Neurol; 2024 Feb; 31(2):e16142. PubMed ID: 37975761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living.
    Mendelsohn E; Rosenthal M; Bohiri Y; Werber E; Kotler M; Strous RD
    Int Clin Psychopharmacol; 2004 Nov; 19(6):319-24. PubMed ID: 15486516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivastigmine for subcortical vascular dementia.
    Román GC
    Expert Rev Neurother; 2005 May; 5(3):309-13. PubMed ID: 15938663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding changes in cholinergic function: implications for treating dementia.
    J Clin Psychiatry; 2002 Mar; 63(3):259-69. PubMed ID: 11926730
    [No Abstract]   [Full Text] [Related]  

  • 16. Cholinesterase inhibitors for Parkinson's disease dementia.
    Maidment I; Fox C; Boustani M
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
    Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
    Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivastigmine in vascular dementia.
    Vincent S; Lane R
    Int Psychogeriatr; 2003; 15 Suppl 1():201-5. PubMed ID: 16191241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivastigmine for vascular cognitive impairment.
    Birks J; McGuinness B; Craig D
    Cochrane Database Syst Rev; 2013 May; (5):CD004744. PubMed ID: 23728651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.